JP2005527495A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005527495A5 JP2005527495A5 JP2003565430A JP2003565430A JP2005527495A5 JP 2005527495 A5 JP2005527495 A5 JP 2005527495A5 JP 2003565430 A JP2003565430 A JP 2003565430A JP 2003565430 A JP2003565430 A JP 2003565430A JP 2005527495 A5 JP2005527495 A5 JP 2005527495A5
- Authority
- JP
- Japan
- Prior art keywords
- linker
- ligand
- och
- acceptor moiety
- oco
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003446 ligand Substances 0.000 claims 57
- 150000001875 compounds Chemical class 0.000 claims 51
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 108010078791 Carrier Proteins Proteins 0.000 claims 29
- 102000005962 receptors Human genes 0.000 claims 29
- 108020003175 receptors Proteins 0.000 claims 29
- 125000003342 alkenyl group Chemical group 0.000 claims 26
- 125000000304 alkynyl group Chemical group 0.000 claims 25
- 229910052760 oxygen Inorganic materials 0.000 claims 20
- 229910052717 sulfur Inorganic materials 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 16
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 16
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 11
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 229910002091 carbon monoxide Inorganic materials 0.000 claims 8
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 claims 7
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 claims 7
- 239000003937 drug carrier Substances 0.000 claims 7
- 150000002924 oxiranes Chemical class 0.000 claims 7
- MZAGXDHQGXUDDX-JSRXJHBZSA-N (e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/C(N)=O MZAGXDHQGXUDDX-JSRXJHBZSA-N 0.000 claims 6
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 6
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 5
- -1 isobutyl Phenyl Chemical group 0.000 claims 5
- 229940076279 serotonin Drugs 0.000 claims 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 5
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 150000004702 methyl esters Chemical class 0.000 claims 4
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical compound CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 125000004434 sulfur atom Chemical group 0.000 claims 4
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 claims 3
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 230000007017 scission Effects 0.000 claims 3
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims 2
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 2
- 102000017910 Adrenergic receptor Human genes 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 claims 2
- 108050007331 Cannabinoid receptor Proteins 0.000 claims 2
- 102000018899 Glutamate Receptors Human genes 0.000 claims 2
- 108010027915 Glutamate Receptors Proteins 0.000 claims 2
- 101710138657 Neurotoxin Proteins 0.000 claims 2
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 claims 2
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 claims 2
- 102000003840 Opioid Receptors Human genes 0.000 claims 2
- 108090000137 Opioid Receptors Proteins 0.000 claims 2
- 101710164184 Synaptic vesicular amine transporter Proteins 0.000 claims 2
- 102100034333 Synaptic vesicular amine transporter Human genes 0.000 claims 2
- 102000016981 Trace amine receptors Human genes 0.000 claims 2
- 108070000027 Trace amine receptors Proteins 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 229960003638 dopamine Drugs 0.000 claims 2
- 239000002581 neurotoxin Substances 0.000 claims 2
- 231100000618 neurotoxin Toxicity 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 claims 2
- PPABWZVICOTUPJ-UHFFFAOYSA-N 3-(oxiran-2-yl)propanoic acid Chemical compound OC(=O)CCC1CO1 PPABWZVICOTUPJ-UHFFFAOYSA-N 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 102000015554 Dopamine receptor Human genes 0.000 claims 1
- 108050004812 Dopamine receptor Proteins 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 claims 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000006491 negative regulation of transport Effects 0.000 claims 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical group C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229930004006 tropane Natural products 0.000 claims 1
- 0 C*(CCC1)C*C1C(*)N Chemical compound C*(CCC1)C*C1C(*)N 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35511102P | 2002-02-08 | 2002-02-08 | |
| US36740002P | 2002-03-25 | 2002-03-25 | |
| PCT/US2003/004023 WO2003066004A2 (en) | 2002-02-08 | 2003-02-10 | Therapeutic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005527495A JP2005527495A (ja) | 2005-09-15 |
| JP2005527495A5 true JP2005527495A5 (cg-RX-API-DMAC10.html) | 2006-03-30 |
Family
ID=27737484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565430A Pending JP2005527495A (ja) | 2002-02-08 | 2003-02-10 | 治療化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7439264B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1478356A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2005527495A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2003215150A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2476218A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2003066004A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100143248A1 (en) * | 1999-06-28 | 2010-06-10 | President And Fellows Of Harvard College | Methods for diagnosing and monitoring treatment of adhd by assessing the dopamine transporter level |
| WO2001068104A1 (en) * | 2000-03-16 | 2001-09-20 | The Mclean Hospital Corporation | Compounds for the treatment of psychiatric or substance abuse disorders |
| US7550485B2 (en) * | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
| WO2005122767A1 (en) * | 2004-06-10 | 2005-12-29 | Mclean Hospital Corporation | Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
| EP1765364A4 (en) * | 2004-06-10 | 2010-09-22 | Mclean Hospital Corp | PYRIMIDINES, SUCH AS Z: B: CYTIDINE, IN THE TREATMENT OF PATIENTS WITH BIPOLAR DISORDER |
| US7947661B2 (en) * | 2004-08-11 | 2011-05-24 | The Mclean Hospital Corporation | Compounds for the treatment of marihuana dependence, withdrawal, and usage |
| US20060069086A1 (en) * | 2004-09-23 | 2006-03-30 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| WO2007100775A2 (en) * | 2006-02-27 | 2007-09-07 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| GB2447949B (en) * | 2007-03-29 | 2010-03-31 | Renasci Consultancy Ltd | A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission |
| US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
| US8697888B2 (en) * | 2012-01-06 | 2014-04-15 | Vanderbilt University | Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6531483B1 (en) | 1990-08-09 | 2003-03-11 | Research Triangle Institute | Cocaine receptor binding ligands |
| US6241963B1 (en) | 1995-10-19 | 2001-06-05 | The Trustees Of The University Of Pennsylvania | Dopamine and serotonin transporter ligands and imaging agents |
| US5948933A (en) | 1997-07-11 | 1999-09-07 | Organix, Inc. | Tropane analogs and methods for inhibition of monoamine transport |
| AU1797700A (en) | 1998-12-14 | 2000-07-03 | Nuclear Receptor Research Limited | Novel ligands of nuclear receptor |
| CA2721484A1 (en) | 1999-05-12 | 2000-11-12 | President And Fellows Of Harvard College | Dopamine transporter imaging agents |
| US6479509B1 (en) | 2000-05-22 | 2002-11-12 | Research Triangle Institute | Method of promoting smoking cessation |
| US6525206B1 (en) * | 2000-10-17 | 2003-02-25 | President And Fellows Of Harvard College | Compounds with high monoamine transporter affinity |
| GB2380733A (en) | 2001-10-11 | 2003-04-16 | Bertha Kalifon Madras | Non-amine tropane analogues |
-
2003
- 2003-02-10 WO PCT/US2003/004023 patent/WO2003066004A2/en not_active Ceased
- 2003-02-10 JP JP2003565430A patent/JP2005527495A/ja active Pending
- 2003-02-10 AU AU2003215150A patent/AU2003215150A1/en not_active Abandoned
- 2003-02-10 CA CA002476218A patent/CA2476218A1/en not_active Abandoned
- 2003-02-10 EP EP03710964A patent/EP1478356A4/en not_active Withdrawn
- 2003-02-10 US US10/364,028 patent/US7439264B2/en not_active Expired - Lifetime
-
2008
- 2008-10-21 US US12/255,650 patent/US20090048284A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2500678C2 (ru) | Замещенные хиноксалинового типа мостиковые пиперидиновые соединения и их применение | |
| AR019478A1 (es) | Ligandos derivados de piperidina de alta afinidad para el receptor de nociceptina orl-1, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos. | |
| HUP0301427A2 (hu) | Fotokemoterápiában alkalmazható fotoszenzitizáló, 5-aminolevulinsavészterek azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| AR063872A1 (es) | Derivados de acetileno como inhibidores de estearoil coa desaturasa | |
| JP2008525416A5 (cg-RX-API-DMAC10.html) | ||
| KR920012061A (ko) | α-옥소아세트아미드 유도체 | |
| DE122007000065I2 (de) | 3,3-diphenylpropylaminderivate | |
| EP2754454A3 (en) | Non-steroidal anti-inflammatory drug derivatives | |
| KR880009020A (ko) | 신규 치료법 | |
| KR930703305A (ko) | 5-헤테로일 인돌 유도체 | |
| AR035479A1 (es) | Derivados de eteres biarilicos y sus sales, composiciones farmaceuticas que los comprenden y procedimientos para el tratamiento de trastornos o afecciones | |
| JP2010540638A5 (cg-RX-API-DMAC10.html) | ||
| WO2007099162A3 (fr) | Derive de resveratrol a longue chaine hydroxylee utiles comme neurotrophiques | |
| JP2006507220A5 (cg-RX-API-DMAC10.html) | ||
| JP2004527567A5 (cg-RX-API-DMAC10.html) | ||
| KR930700451A (ko) | 항암제로서의 비스-나프탈이미드 | |
| RU2003134629A (ru) | Соединения цефема | |
| JP2005511833A5 (cg-RX-API-DMAC10.html) | ||
| ES397786A1 (es) | Procedimiento para la obtencion de derivados piperidinicos. | |
| BRPI0509390A (pt) | derivados de 1-(1h-indol-1-il)-3-(4-metilpiperazin-1-il)-fenil propan-2-ol e compostos relacionados como moduladores da atividade da norepinefrina (ne) e da serotonina (5-th) e da reabsorção da monoamina para o tratamento de sintomas vasomotores (vms) | |
| IE44739B1 (en) | Adenine derivatives | |
| CA2535511A1 (en) | Compounds having thrombopoietin receptor agonism | |
| WO2007079470A3 (en) | Therapeutic amine-arylsulfonamide conjugate compounds | |
| Pifferi et al. | The cost benefit ratio of enantiomeric drugs | |
| KR910000607A (ko) | 새로운 에스테르 |